Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...

The campaign is presented by Daiichi-Sankyo and AstraZeneca, while Merck serves as a gold-level sponsor and Eli Lilly, Pfizer and Guardant come aboard as community sponsors. In the campaign’s ...

Japan’s Daiichi Sankyo has joined an open innovation research initiative that will try to develop a therapy for type 1 diabetes based on insulin-producing cells. The drugmaker has teamed up with ...

Daiichi Sankyo Co. will seek to maintain its edge over competitors in precision cancer therapies, by pushing ahead with clinical trials of drug candidates being developed using new technology, a ...

Dai-Ichi Karkare Limited (DIKL) was set up in 1960 as a private limited company for the manufacture of speciality chemicals. The Company entered into technical collaboration with the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Dai-ichi Life Insurance Co. announced on Oct. 29 it will lower the estimated rate of return for the defined benefit corporate pension insurance policies it has contracted with about 3,000 ...

A DAIICHI representative stated, "Indonesia is one of the countries with the most islands in the world, and since travel is a part of daily life, there are many families traveling with children.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Hiroyuki Okuzawa, President and COO at Daiichi Sankyo, says the company is working to boost production of its newer-generation cancer therapies that target diseased cells, across Japan ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...